drugset
drugset / Trial / NCT00790322

Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy

NCT00790322 ↗

Phase 3 Completed 130 enrolled Biotec Pharmacon ASA
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SBG vs placebo on oral mucositis in head and neck cancer patients undergoing radiation therapy.

Timeline

Start
2008-10
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject soluble beta-1,3/1,6-glucan Unknown — Oral

Indications

head and neck cancer mucositis